Anastrozole

Generic Name: Anastrozole

Brand Names: Arimidex

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₉N_₅

CAS Number: 120511-73-1

Unique Ingredient Identifier: 2Z07MYW1AZ

Background: Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and acne. Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators such as tamoxifen.

Anastrozole was first approved for use in the United States in 1995.

Indication: Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in postmenopausal women who experience disease progression despite treatment with tamoxifen.

Associated Conditions: Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer

Associated Therapies: -

Clinical Trials

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Early-Stage Breast Carcinoma
Hormone Receptor Positive Tumor

Interventions: Drug: Abemaciclib
Drug: Loperamide
Drug: Anastrozole

First Posted Date: 2015-05-12

Last Posted Date: 2020-06-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 224

Registration Number: NCT02441946

Locations: 🇺🇸
Millennium Oncology, Houston, Texas, United States
🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Taipei, Taiwan
🇺🇸
Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States

and more 28 locations

Detect V / CHEVENDO (Chemo vs. Endo)

Phase 3

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: pertuzumab
Drug: Trastuzumab
Drug: nab-Paclitaxel
Drug: eribulin
Drug: Letrozole
Drug: Docetaxel
Drug: Paclitaxel
Drug: Vinorelbine
Drug: Exemestane
Drug: Capecitabine
Drug: Fulvestrant
Drug: Anastrozole
Drug: leuprorelin
Drug: Ribociclib
Drug: goserelin

First Posted Date: 2015-01-26

Last Posted Date: 2024-06-04

Lead Sponsor: Prof. Wolfgang Janni

Target Recruit Count: 271

Registration Number: NCT02344472

Locations: 🇩🇪
University Hospital Ulm Gynecology/Obstetrics, Ulm, Germany

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Everolimus
Drug: Exemestane
Drug: Tamoxifen
Drug: Fulvestrant
Drug: Anastrozole
Drug: Letrozole
Drug: Toremifine

First Posted Date: 2014-11-17

Last Posted Date: 2020-02-17

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 48

Registration Number: NCT02291913

Locations: 🇺🇸
Woodlands Medical Specialists, Pensacola, Florida, United States
🇺🇸
Hope Cancer Center, Terre Haute, Indiana, United States
🇺🇸
Center for Cancer and Blood Disorders, Fort Worth, Texas, United States

and more 5 locations

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Phase 3

Completed

Conditions: Advanced Metastatic Breast Cancer

Interventions: Drug: Tamoxifen
Drug: Ribociclib
Drug: Letrozole
Drug: Anastrozole
Drug: Goserelin
Drug: Placebo

First Posted Date: 2014-10-29

Last Posted Date: 2024-03-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 672

Registration Number: NCT02278120

Locations: 🇺🇸
Penn State University Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸
Danbury Hospital SC, Danbury, Connecticut, United States
🇺🇸
University Of California Los Angeles Dept of Onc, Los Angeles, California, United States

and more 33 locations

Phase II Study of Everolimus Beyond Progression

Phase 2

Terminated

Conditions: Estrogen Receptor-positive Breast Cancer
HER2-negative Breast Cancer
Progesterone Receptor-positive Breast Cancer
Stage IIIA Breast Cancer
Stage IV Breast Cancer
Recurrent Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer

Interventions: Drug: everolimus
Drug: anastrozole
Drug: letrozole
Drug: tamoxifen citrate
Drug: fulvestrant
Drug: megestrol acetate

First Posted Date: 2014-10-21

Last Posted Date: 2022-04-05

Lead Sponsor: Emory University

Target Recruit Count: 3

Registration Number: NCT02269670

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

Testosterone Regulation of the Natriuretic Peptide System

Not Applicable

Withdrawn

Conditions: Hypertension

Interventions: Drug: Testosterone
Drug: Nesiritide
Drug: Anastrozole
Drug: Leuprolide
Drug: Placebo

First Posted Date: 2014-10-20

Last Posted Date: 2017-10-19

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT02269072

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Abemaciclib
Drug: Anastrozole
Drug: Placebo
Drug: Letrozole

First Posted Date: 2014-09-23

Last Posted Date: 2024-10-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 493

Registration Number: NCT02246621

Locations: 🇦🇹
Universitaetsklinikum Allgemeines Krankenhaus Wien, Vienna, Wien, Austria
🇯🇵
Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan
🇺🇸
Ironwood Cancer & Research Centers, Chandler, Arizona, United States

and more 131 locations

Endocrine Response in Women With Invasive Lobular Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Anastrozole
Drug: Tamoxifen
Drug: Fulvestrant

First Posted Date: 2014-08-01

Last Posted Date: 2024-08-22

Lead Sponsor: Priscilla McAuliffe

Target Recruit Count: 201

Registration Number: NCT02206984

Locations: 🇺🇸
Univ. of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
ALBERT EINSTEIN COLLEGE OF MEDICINE Montefiore Medical Center, Bronx, New York, United States
🇺🇸
Josh Plassmeyer, Pittsburgh, Pennsylvania, United States

and more 9 locations

Bay98-7196, Dose Finding / POC Study

Phase 2

Completed

Conditions: Endometriosis

Interventions: Drug: Placebo
Drug: Lupron / Leuprolide acetate
Drug: Levonorgestrel
Drug: Anastrozole

First Posted Date: 2014-07-29

Last Posted Date: 2023-11-07

Lead Sponsor: Bayer

Target Recruit Count: 319

Registration Number: NCT02203331

ER Reactivation Therapy for Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: 17B-estradiol
Drug: Letrozole
Drug: Anastrozole
Drug: Exemestane

First Posted Date: 2014-07-14

Last Posted Date: 2024-07-17

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 19

Registration Number: NCT02188745

Locations: 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Baystate Medical Center, Springfield, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy